THE FIRST AND ONLY ADJUVANT, TARGETED TREATMENT
For ALK+ RESECTED NSCLC1

Not a real patient.

REDUCING

THE RISK 

OF DISEASE

RECURRENCE 

OR DEATH BY


76%

ALECENSA delivered superior disease-free survival vs platinum-based chemotherapy2

  • In the ITT population, median DFS was not reached for ALECENSA (95% CI: NE, NE) vs 41.3 months (95% CI: 28.5, NE) for chemotherapy (HR=0.24 [95% CI: 0.13, 0.43]; p<0.001)2
  • Median survival follow-up: ALECENSA: 27.8 months; chemotherapy: 28.4 months2

Explore the ALINA data

Efficacy Safety

Fast facts

<50%

of patients with early-stage NSCLC are diagnosed and treated in the curative setting4,5

Fast facts

The 5-year recurrence rate in resected NSCLC
ranges from 45-76% depending on disease stage6

Fast facts

Testing for ALK rearrangements is recommended
in patients with resected, early-stage NSCLC3

ALK: anaplastic lymphoma kinase; Cl: confidence interval; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NCCN: National Comprehensive Cancer Network; NE: not estimable; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer v.5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved (accessed July 2024). To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way; 4. Uldbjerg EM, et al. Cancers (Basel) 2023;15(21):5130; 5. EpiCast report: NSCLC Epidemiology Forecast to 2029. GlobalData. 2020; 6. Lim JU. Tuberc Respir Dis (Seoul) 2023;86(1):14–22.